Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Plus mFOLFOX6 and SCRT in pMMR/MSS Locally Advanced Rectal Cancer
NCT07175636Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in rectal cancer, sponsored by Sun Yat-sen University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07175636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07175636.